Research or work at IFReC

• To researchers

  IFReC is a world leading organization using the latest techniques to research in various fields including virology, cell biology and parasitology with a focus on immunology.

  Laboratories

  Recruit

• To university students

  IFReC welcomes highly motivated students in life science research regardless of the university or department. Principal Investigators (PIs) at IFReC are from the Osaka University Graduate School of Medicine, Graduate School of Frontier Biosciences and the Graduate School of Engineering.

• To high-school students

  In principle, in order to do research at IFReC, postgraduate study at the Osaka University Graduate School of Medicine, Graduate School of Frontier Biosciences or Graduate School of engineering is required. In order to do so, it is advisable to take examinations to a school that allows entrance to one of these graduate schools. For example, to enter the Graduate School of Engineering it is best to first enter the School of Engineering. It is possible to enter from other universities and other departments. If you have a strong desire to research at IFReC, gather as much information as you can beforehand.

• IFReC Advanced Postdoc Program

  2024.07.01

  IFReC offers outstanding young researchers opportunities to work with field-leading researchers as well as to conduct their own research and publish under their own merit. The Center has established the Advanced Postdoc Program and is recruiting promising young researchers in fields of immunology and cell biology.

  Click Here For More Info

• IFReC Kishimoto Foundation Fellowship

  2024.03.18

  The purpose of this program is to support international researchers in order to promote the globalization and development of immunological research at IFReC. The fellowship was set up in 2008 by IFReC Professor Tadamitsu Kishimoto (former president of Osaka University) who discovered interleukin-6 (IL-6), a vital molecule in the research and treatment of autoimmune diseases such as rheumatoid arthritis and developer of an IL-6 receptor antibody, Tocilizumab.

  Click Here For More Info